Characteristic | Estimate of effect HR (95% CI) | P value | q-value* |
Probable CAPA | 1.15 (0.68 to 1.95) | 0.59 | 0.72 |
Female gender | 0.76 (0.51 to 1.12) | 0.17 | 0.47 |
Age (per 5-year increase) | 1.15 (1.07 to 1.25) | <0.001 | 0.002 |
Ethnicity | |||
White | — | ||
Asian | 1.40 (0.93 to 2.11) | 0.11 | 0.37 |
Black | 0.76 (0.43 to 1.37) | 0.36 | 0.68 |
Other | 1.23 (0.70 to 2.16) | 0.48 | 0.68 |
COPD | 2.39 (1.21 to 4.71) | 0.012 | 0.051 |
Smoking history | 1.18 (0.78 to 1.78) | 0.43 | 0.68 |
BMI (per point increase) | 0.99 (0.96 to 1.02) | 0.42 | 0.68 |
Diabetes | 0.88 (0.59 to 1.31) | 0.52 | 0.69 |
Hypertension | 0.94 (0.66 to 1.36) | 0.76 | 0.86 |
EORTC host criteria | 1.31 (0.64 to 2.68) | 0.46 | 0.68 |
APACHE II (per 3-point increase) | 1.18 (1.09 to 1.27) | <0.001 | <0.001 |
Received ECMO | 0.97 (0.63 to 1.51) | 0.90 | 0.95 |
Received IL-6 inhibitor | 0.82 (0.56 to 1.21) | 0.30 | 0.68 |
Steroid dose 28 days prior to ICU admission (per 100 mg pred-eq) | 1.06 (1.01 to 1.12) | 0.016 | 0.056 |
Possible CAPA classified as no CAPA for this analysis. Bold values denote statistical significance at the p < 0.05 level.
*False discovery rate correction for multiple testing.
APACHE II, Acute Physiology and Chronic Health Evaluation II; BMI, body mass index; CAPA, COVID-19-associated pulmonary aspergillosis; COPD, chronic obstructive pulmonary disease; ECMO, extracorporeal membrane oxygenation; EORTC, European Organization for Research and Treatment of Cancer; ICU, intensive care unit; IL, interleukin; pred-eq, prednisolone equivalent.